|
クレバヤシ ジュンイチ
Junichi Kurebayashi
紅林 淳一 所属 川崎医療福祉大学 医療技術学部 臨床工学科 職種 特任教授 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model. |
| 掲載誌名 | 正式名：Anticancer research 略 称：Anticancer Res ISSNコード：02507005 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 40(5),pp.2475-2479 |
| 著者・共著者 | Yamamoto Jun, MurataTakuya, Sugisawa Norihiko, Higuchi Takashi, Tashiro Yoshihiko, Nishino Hiroto, Inubushi Sachiko, Sun YU, Lim Hyein, Miyake Kentaro, Shimoya Koichiro, Nomura Tsunehisa, Kurebayashi Junichi, Tanino Hirokazu, Hozumi Chihiro, Bouvet Michael, Singh Shree Ram, Endo Itaru, Hoffman Robert M |
| 発行年月 | 2020/05 |
| 概要 | Abstract
Background/aim: Matrix-producing breast carcinoma (MPBC) is a rare and usually aggressive triple-negative breast cancer (TNBC). In the present report, we determined the drug sensitivity for a triple-negative MPBC using a patient-derived orthotopic xenograft (PDOX) model. Materials and methods: The PDOX model was established in the left 2nd mammary by surgical orthotopic implantation (SOI). MPBC PDOX models were randomized into 4 groups (6 mice per group) when the tumor volume became 80 mm3: G1, control group; G2, cisplatinum group [intraperitoneal (i.p.) injection, weekly, for 2 weeks]; G3, paclitaxel group (i.p., weekly, for 2 weeks); G4, eribulin group [intravenous (i.v.) injection, weekly, for 2 weeks]. All mice were sacrificed on day 15. Tumor volume and body weight were measured one time per week. Results: The MPBC PDOX model was resistant to cisplatinum (p=0.800). Paclitaxel suppressed tumor growth compared to the control group (p=0.009). However, only eribulin regressed the tumor (p=0.001). Conclusion: Eribulin has clinical potential for triple-negative MPBC patients. |
| DOI | 10.21873/anticanres.14217 |
| PMID | 32366391 |